These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28243577)

  • 21. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey.
    Muenzer J; Beck M; Giugliani R; Suzuki Y; Tylki-Szymanska A; Valayannopoulos V; Vellodi A; Wraith JE
    Genet Med; 2011 Feb; 13(2):102-9. PubMed ID: 21233716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.
    Muenzer J; Beck M; Eng CM; Giugliani R; Harmatz P; Martin R; Ramaswami U; Vellodi A; Wraith JE; Cleary M; Gucsavas-Calikoglu M; Puga AC; Shinawi M; Ulbrich B; Vijayaraghavan S; Wendt S; Conway AM; Rossi A; Whiteman DA; Kimura A
    Genet Med; 2011 Feb; 13(2):95-101. PubMed ID: 21150784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II.
    Kim KH; Messinger YH; Burton BK
    Mol Genet Metab Rep; 2015 Mar; 2():20-24. PubMed ID: 28649520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature.
    Pérez-López J; Moltó-Abad M; Muñoz-Delgado C; Morales-Conejo M; Ceberio-Hualde L; Del Toro M
    Mol Genet Metab; 2018 Jul; 124(3):216-227. PubMed ID: 29801985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
    Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH
    Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II.
    Ngu LH; Ong Peitee W; Leong HY; Chew HB
    Mol Genet Metab Rep; 2017 Sep; 12():28-32. PubMed ID: 28540187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II.
    Seo JH; Kosuga M; Hamazaki T; Shintaku H; Okuyama T
    Mol Ther Methods Clin Dev; 2021 Jun; 21():67-75. PubMed ID: 33768130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey.
    Burton BK; Guffon N; Roberts J; van der Ploeg AT; Jones SA;
    Mol Genet Metab; 2010; 101(2-3):123-9. PubMed ID: 20638311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy outcomes across the disease spectrum: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program.
    Harmatz PR; Lampe C; Parini R; Sharma R; Teles EL; Johnson J; Sivam D; Sisic Z
    J Inherit Metab Dis; 2019 May; 42(3):519-526. PubMed ID: 30834539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase.
    Hogan MJ; Stephens K; Smith E; Jalazo ER; Hendriksz CJ; Edwards LJ; Bjoraker KJ
    Mol Genet Metab Rep; 2020 Dec; 25():100669. PubMed ID: 33101985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).
    Jones SA; Parini R; Harmatz P; Giugliani R; Fang J; Mendelsohn NJ;
    Mol Genet Metab; 2013 May; 109(1):41-8. PubMed ID: 23537841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial.
    Okuyama T; Eto Y; Sakai N; Minami K; Yamamoto T; Sonoda H; Yamaoka M; Tachibana K; Hirato T; Sato Y
    Mol Ther; 2019 Feb; 27(2):456-464. PubMed ID: 30595526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
    Felice BR; Wright TL; Boyd RB; Butt MT; Pfeifer RW; Pan J; Ruiz JA; Heartlein MW; Calias P
    Toxicol Pathol; 2011 Aug; 39(5):879-92. PubMed ID: 21628718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of idursulfase beta and idursulfase in vitro and in vivo.
    Kim C; Seo J; Chung Y; Ji HJ; Lee J; Sohn J; Lee B; Jo EC
    J Hum Genet; 2017 Feb; 62(2):167-174. PubMed ID: 27829684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.